Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from AMGEN

14:57 EDT 16th June 2019 | BioPortfolio

Here are the most relevant search results for "AMGEN" found in our extensive news archives from over 250 global news sources.

More Information about AMGEN on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about AMGEN for you to read. Along with our medical data and news we also list AMGEN Clinical Trials, which are updated daily. BioPortfolio also has a large database of AMGEN Companies for you to search.

Showing News Articles 1–25 of 67 from AMGEN

Thursday 13th June 2019

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTI™ (trastuzumab-anns) for all approved indications of the referenc...

Wednesday 12th June 2019

Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution

THOUSAND OAKS, Calif., June 12, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press rel...

Friday 7th June 2019

Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

THOUSAND OAKS, Calif., June 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 11:20 a.m. PT on Wednesday, June 12, 2019, in Rancho Palos Verdes, Calif. David M. Reese, M.D., executive vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Ev...

Monday 3rd June 2019

Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019

AMG 510 is the First KRASG12C Inhibitor to Reach Clinical Stage After Three Decades of RAS Research First-In-Human Results Show Preliminary Safety, Tolerability Data and Anti-Tumor Activity in KRAS Mutant Solid Tumors FDA Grants AMG 510 Orphan Drug Designation for KRASG12C-Positive Non-Small Cell Lung and Colorectal Cancers THOUSAND OAKS, Calif., June 3, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN...

Sunday 2nd June 2019

Amgen Highlights The Versatility Of The BiTE® Immuno-Oncology Platform In Multiple Tumor Types At ASCO 2019

Updated Phase 1 Data of Investigational AMG 420 in Relapsed and/or Refractory Multiple Myeloma Highlighted in Oral Presentation and Accepted for Best of ASCO® Investigational AMG 212 (Pasotuxizumab) Phase 1 Study Explores Use of BiTE Platform in a Solid Tumor THOUSAND OAKS, Calif., June 2, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from Phase 1 studies evaluating inves...

Wednesday 29th May 2019

Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)

THOUSAND OAKS, Calif., May 29, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will host a webcast investor meeting at ASCO 2019 on Monday, June 3 at 6:30 p.m. CT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team and clinical investigators, will participate at the investor meeting to discuss Amgen's oncology pro...

Tuesday 21st May 2019

Amgen Announces Voting Results Of Annual Meeting Of Stockholders

THOUSAND OAKS, Calif., May 21, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 89 percent of outstanding shares were represented at the meeting. The director nominees Wanda M. Austin, Robert A. Bradway, Brian J. Druker, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecc...

Thursday 16th May 2019

Amgen To Present At The RBC Healthcare Conference And The UBS Global Healthcare Conference

THOUSAND OAKS, Calif., May 16, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the RBC Health Care Conference at 8:30 a.m. ET and at the UBS Global Healthcare Conference at 2 p.m. ET on Tuesday, May 21, 2019, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at both conferences. Live audio of the presentation can be accessed from ...

Wednesday 15th May 2019

Amgen Showcases Oncology Pipeline At ASCO 2019

Data From Largest Oncology Pipeline in Company's History First-in-Human Data Evaluating Investigational AMG 510, the First KRASG12C Inhibitor to Reach Clinical Stage, in Solid Tumors Potential Versatility of BiTE® Immuno-oncology Platform Reinforced With Phase 1 Asset Updates THOUSAND OAKS, Calif., May 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that data from its oncology p...

Friday 10th May 2019

Amgen To Present At The Bank of America Merrill Lynch 2019 Health Care Conference

THOUSAND OAKS, Calif., May 10, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2019 Health Care Conference at 10 a.m. PT on Wednesday, May 15, 2019. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www....

Monday 6th May 2019

Amgen Sets Official Guinness World Record™ for Most Osteoporosis Screenings for an Osteoporosis Campaign in 24 Hours

Healthcare Campaign  Executed Across 10 Countries to Raise Awareness of the Importance of Predicting  and Preventing Osteoporosis and Bone Fracture, Particularly in Post-Menopausal  WomenThousand Oaks, Calif. (May 6, 2019) – Amgen, together with local healthcare partners in 10 countries around the  world, set on May 5, 2019, a Guinness World Record title for the most  os...

Thursday 2nd May 2019

Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting

After Long-Term Aimovig Treatment, Two-Thirds of Chronic Migraine Patients Converted to Episodic Migraine, Experiencing 11 Fewer Migraine Days per Month on Average Separate Study Showed the Majority of Episodic Migraine Patients on Aimovig Reported at Least a 50 Percent Reduction in Monthly Migraine Days at One Year, With One in Five Being Completely Migraine-Free Aimovig is the Most Prescribed ...

Wednesday 1st May 2019

Amgen Ignites A Social Fitness Movement To Support The Fight Against Heart Disease And Cancer

Amgen Breakaway Challenge Turns Walking, Running or Cycling Miles Into Support for Eight Independent Nonprofit Advocacy Organizations THOUSAND OAKS, Calif., May 1, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support the fight against heart disease and ca...

Tuesday 30th April 2019

Amgen Reports First Quarter 2019 Financial Results

THOUSAND OAKS, Calif., April 30, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2019. Key results include: Total revenues were unchanged at $5.6 billion in comparison to the first quarter of 2018. Product sales declined 1 percent globally. New and recently launched products including Prolia® (denosumab), Repatha® (evolocumab) ...

Thursday 25th April 2019

Amgen Announces Webcast of 2019 First Quarter Financial Results

THOUSAND OAKS, Calif., April 25, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Tuesday, April 30, 2019, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and ch...

Wednesday 17th April 2019

Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida

Long-Established Science Education Program to Give Local Secondary School Students Hands-On Biotechnology Lab Experience TAMPA, Fla., April 17, 2019 /PRNewswire/ -- The Amgen Foundation, together with the University of South Florida (USF), today announced the launch of the Amgen Biotech Experience (ABE) program in Tampa, Florida, as part of its long-standing science education program. Globally,...

Monday 15th April 2019

EVENITY™ (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

New Therapy to Cost One-Third Less Than Other Bone-Building Agents Over Full Course of Therapy THOUSAND OAKS, Calif., April 15, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that EVENITY™ (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on April 9, 2019, for the treatment of osteoporosis...

Tuesday 9th April 2019

FDA Approves EVENITY™ (romosozumab-aqqg) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

One in Two Women in the United States Will Suffer a Fracture in Her Lifetime Due to Osteoporosis(1) EVENITY is the First and Only Bone Builder With a Dual Effect That Both Increases Bone Formation and Decreases Bone Loss(2) EVENITY Rapidly Reduces Fracture Risk and Builds New Bone With 12 Months of Therapy(2) THOUSAND OAKS, Calif. and BRUSSELS, April 9, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMG...

Sunday 7th April 2019

Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe

Study Shows 55 Percent of Women Over 70 Years Old are at Risk of Fragility Fractures With 75 Percent of Them not Treated for Osteoporosis THOUSAND OAKS, Calif., April 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data presented from a cross-sectional study revealing a gap in the diagnosis and treatment of osteoporosis in Europe. The real-world study of osteoporosis management ...

Wednesday 20th March 2019

Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis

Data Monitoring Committee Recommends Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure to Continue Without Changes THOUSAND OAKS, Calif., and SOUTH SAN FRANCISCO, Calif., and SURESNES, France, March 20, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that the Data Monitoring Committee (DMC) for GALACTIC...

Friday 15th March 2019

Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke

VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations Phase 3 Study Will Enroll High-Risk Patients who Have Significant Atherosclerotic Disease or Diabetes and are at High Risk for a First Cardiovascular Event THOUSAND OAKS, Calif., March 15, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans t...

Tuesday 12th March 2019

Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk

If You've had a Heart Attack or Stroke, Your Risk of Having Another Cardiovascular Event is Nearly One in Three(1) Cholesterol 911 Urges These High-Risk Patients to See the Emergency in High Cholesterol and Talk to Their Doctor About Ways to Reduce the Risk of Another Heart Attack and Stroke THOUSAND OAKS, Calif., March 12, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today launched Cholesterol 91...

Thursday 7th March 2019

Amgen Announces 2019 Second Quarter Dividend

THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. The dividend will be paid on June 7, 2019, to all stockholders of record as of the close of business on May 17, 2019. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering fro...

Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference

THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019, in Boston. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's webs...

Wednesday 6th March 2019

New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations

Results From TAUSSIG Study Reinforce Repatha's Safety and Efficacy in Patients With Genetic Risk of High Cholesterol Several Real-World Evidence Studies Highlight Continued Unmet Need and Suboptimal Treatment of High-Risk Cardiovascular Disease Patients THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of nine cardiovascular scientific re...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks